Ventas (VTR)
(Delayed Data from NYSE)
$64.45 USD
+1.23 (1.95%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $64.43 -0.02 (-0.03%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.45 USD
+1.23 (1.95%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $64.43 -0.02 (-0.03%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Zacks News
Crown Castle's (CCI) Q4 AFFO Beat Estimate, Revenues Down Y/Y
by Zacks Equity Research
Crown Castle's (CCI) Q4 results outshine estimates on better-than-anticipated revenues. However, high interest expense is a concern. It has maintained its 2024 outlook.
Crown Castle's (CCI) Q4 AFFO Beat, Site-Rental Revenues Up
by Zacks Equity Research
Crown Castle's (CCI) Q4 earnings outshine estimates on elevated fiber segment revenues. Site-rental revenues grow year over year, aiding the top line.
Here's Why Investors Should Retain Ventas (VTR) Stock for Now
by Zacks Equity Research
A rise in healthcare spending by senior citizens and accretive investments in the research portfolio bode well for Ventas (VTR). However, dependence on a few tenants and high interest rates are woes.
Ventas' (VTR) Q3 FFO Beat on SHOP NOI Growth, '23 View Revised
by Zacks Equity Research
Ventas's (VTR) Q3 earnings outshine estimates on better-than-anticipated revenues. The same-store cash NOI rises year over year on strong performance across the portfolio. The company has revised its 2023 outlook.
Compared to Estimates, Ventas (VTR) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Ventas (VTR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Is a Beat in the Offing for Ventas (VTR) in Q3 Earnings?
by Zacks Equity Research
Favorable senior housing operating portfolio operating trends, robust demand for life-science real-estate assets and accretive investments are likely to have benefited Ventas' (VTR) Q3 earnings.
Regency Centers (REG) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Healthy demand for Regency Centers' (REG) shopping centers and gains from accretive acquisitions are likely to have benefited its Q3 earnings. However, higher interest rates might have ailed.
Factors to Impact Innovative Industrial's (IIPR) Q3 Earnings
by Zacks Equity Research
With the cannabis industry gaining prominence, Innovative Industrial's (IIPR) investments in such properties are likely to have aided its Q3 performance, though high expenses might have played a spoilsport.
Key Factors to Impact Boston Properties' (BXP) Q3 Earnings
by Zacks Equity Research
Healthy demand for Boston Properties' (BXP) premium office and life-science assets is likely to have benefited its Q3 earnings. However, higher interest expenses might have hurt it.
What's in the Offing for Host Hotels (HST) in Q3 Earnings?
by Zacks Equity Research
Host Hotels' (HST) Q3 earnings are likely to have benefited from the continued strength in group travel and business transient demand. However, higher interest expenses might have hurt it.
Is a Beat in the Cards for Welltower (WELL) in Q3 Earnings?
by Zacks Equity Research
Welltower's (WELL) Q3 earnings are likely to have benefited from the rise in senior citizen's healthcare expenditure and accretive capital deployment activity.
Is a Beat in Store for Healthpeak (PEAK) in Q3 Earnings?
by Zacks Equity Research
Robust demand for Healthpeak's (PEAK) lab assets and a rise in senior citizen's healthcare expenditure are expected to have benefited its Q3 earnings.
Getty Realty (GTY) Tops Q3 FFO and Revenue Estimates
by Zacks Equity Research
Getty Realty (GTY) delivered FFO and revenue surprises of 1.79% and 9.33%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Investors Should Retain Ventas (VTR) Stock for Now
by Zacks Equity Research
A rise in healthcare spending by senior citizens and accretive investments in the research portfolio bode well for Ventas (VTR). However, dependence on a few tenants and high interest rates are woes.
Ventas (VTR) Partners With Operators for Senior Housing Growth
by Zacks Equity Research
Ventas (VTR) teams up with expert operators to enhance the performance of 26 independent living communities.
Medical Properties (MPW) Beats on Q2 FFO, Narrows '23 View
by Zacks Equity Research
Medical Properties' (MPW) Q2 results reflect lower-than-anticipated revenues. Higher interest expenses during the quarter act as a dampener. The company narrows its 2023 outlook.
Digital Realty (DLR) Unveils Solution to Meet Data Challenges
by Zacks Equity Research
Digital Realty (DLR) unveils high-density colocation service across its global data center platform, PlatformDIGITAL, to help businesses address data and AI growth challenges, and optimize performance.
Four Corners (FCPT) Buys $1.6M Iowa Property, Bolsters Growth
by Zacks Equity Research
Four Corners (FCPT) bolsters its external growth strategy with its recent acquisition of a Jiffy Lube property in Iowa for $1.6 million.
Four Corners (FCPT) Boosts Portfolio With Strategic Buyouts
by Zacks Equity Research
To boost its portfolio with real estate leased to strong credit operators, Four Corners (FCPT) announces the acquisition of a dual-tenant Aspen Dental and WellNow Urgent Care property.
Ventas' (VTR) Q2 FFO Beats, SHOP NOI Up, '23 View Revised
by Zacks Equity Research
Ventas (VTR) posts solid Q2 results on better-than-anticipated revenues. The same-store cash NOI rises year over year on strong performance across the portfolio. The company revises its 2023 outlook.
Compared to Estimates, Ventas (VTR) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Ventas (VTR) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ventas (VTR) Q2 FFO and Revenues Top Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 1.35% and 2.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Robinhood Markets, Inc. (HOOD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Robinhood Markets, Inc. (HOOD) delivered earnings and revenue surprises of 250% and 2.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Extra Space Storage (EXR) in Q2 Earnings?
by Zacks Equity Research
Extra Space Storage's (EXR) Q2 results are likely to reflect gains from high brand value and its solid presence in key cities, while an anticipated rise in vacating volumes is likely to have led to pricing pressure.
What's in the Offing for Regency Centers (REG) in Q2 Earnings?
by Zacks Equity Research
Healthy demand for Regency Centers' (REG) shopping centers, a solid tenant base and gains from accretive acquisitions are likely to have benefited the company's Q2 earnings.